Galcanezumab, marketed under the trade name Emgality, is a humanized monoclonal antibody used for the prevention of migraine. It is also used for cluster headaches.
Common side effects include pain or redness at the site of injection. Other side effects may include hypersensitivity reactions. It is directed against calcitonin-related polypeptides alpha and beta.
This drug was developed by Eli Lilly.